Generation Bio Co.

NasdaqGS:GBIO Rapport sur les actions

Capitalisation boursière : US$178.2m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Generation Bio Gestion

Gestion contrôle des critères 3/4

Le PDG Generation Bio's est Geoff McDonough, nommé en Oct2017, a un mandat de 6.83 ans. La rémunération annuelle totale est $ 2.32M, composée du salaire de 27.2% et des bonus 72.8%, y compris les actions et options de la société. détient directement 2.75% des actions de la société, d'une valeur de $ 4.59M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.3 ans et 6.7 ans.

Informations clés

Geoff McDonough

Directeur général

US$2.3m

Rémunération totale

Pourcentage du salaire du PDG27.2%
Durée du mandat du directeur général6.8yrs
Propriété du PDG2.7%
Durée moyenne d'occupation des postes de direction3.3yrs
Durée moyenne du mandat des membres du conseil d'administration6.7yrs

Mises à jour récentes de la gestion

Recent updates

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

May 01
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Dec 07
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth

Jul 11
Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Mar 11
We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

Nov 19
Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Aug 05
We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Generation Bio GAAP EPS of -$0.66 misses by $0.04

Aug 04

Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth

Apr 20
Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth

Generation Bio: High-Risk, Medium-To-Low-Reward

Dec 30

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Nov 11
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Jul 28
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

Mar 08
Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares

Jan 14
Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares

Generation Bio's insiders on buying spree, stock +4%

Jan 13

Generation Bio prices equity offering at $24.50

Jan 07

Generation Bio files to offer 7.5M shares

Jan 04

Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?

Dec 27
Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?

Generation Bio EPS misses by $0.01

Nov 10

Analyse de la rémunération des PDG

Comment la rémunération de Geoff McDonough a-t-elle évolué par rapport aux bénéfices de Generation Bio?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

-US$158m

Mar 31 2024n/an/a

-US$169m

Dec 31 2023US$2mUS$630k

-US$127m

Sep 30 2023n/an/a

-US$124m

Jun 30 2023n/an/a

-US$127m

Mar 31 2023n/an/a

-US$134m

Dec 31 2022US$4mUS$606k

-US$137m

Sep 30 2022n/an/a

-US$135m

Jun 30 2022n/an/a

-US$136m

Mar 31 2022n/an/a

-US$129m

Dec 31 2021US$6mUS$583k

-US$119m

Sep 30 2021n/an/a

-US$112m

Jun 30 2021n/an/a

-US$101m

Mar 31 2021n/an/a

-US$88m

Dec 31 2020US$2mUS$516k

-US$81m

Sep 30 2020n/an/a

-US$72m

Jun 30 2020n/an/a

-US$68m

Mar 31 2020n/an/a

-US$65m

Dec 31 2019US$593kUS$424k

-US$61m

Rémunération vs marché: La rémunération totale de Geoff ($USD 2.32M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 1.54M ).

Rémunération et revenus: La rémunération de Geoff a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Geoff McDonough (54 yo)

6.8yrs

Titularisation

US$2,315,263

Compensation

Dr. Cameron Geoffrey McDonough, also known as Geoff, M.D. serves as Independent Director of Third Harmonic Bio, Inc. since March 2024. He had been an Independent Director of Surface Oncology, Inc. since Fe...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Cameron McDonough
President6.8yrsUS$2.32m2.75%
$ 4.9m
Matthew Norkunas
Chief Financial Officer4.1yrsUS$1.14m0.082%
$ 146.8k
Matthew Stanton
Chief Scientific Officer5.3yrsUS$1.15m0.37%
$ 657.2k
Yalonda Howze
Chief Legal Officer & Secretary1.3yrsUS$1.21m0.018%
$ 31.6k
Mark Angelino
Co-Founder7.8yrspas de donnéespas de données
Robert Kotin
Co-Founderno datapas de donnéespas de données
Antoinette Paone
Chief Operating Officer2.5yrspas de données0.022%
$ 39.9k
Jasmin Tower
Chief Human Resources Officer1.4yrspas de donnéespas de données
Phillip Samayoa
Chief Strategy Officer1.9yrspas de données0.18%
$ 323.8k

3.3yrs

Durée moyenne de l'emploi

51yo

Âge moyen

Gestion expérimentée: L'équipe de direction de GBIO est considérée comme expérimentée (ancienneté moyenne 3.3 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Cameron McDonough
President6.8yrsUS$2.32m2.75%
$ 4.9m
Jason Rhodes
Independent Chairman6.8yrsUS$181.21k0%
$ 0
Gustav Christensen
Independent Director6.7yrsUS$143.71k0.20%
$ 350.9k
Charles Rowland
Independent Director6.1yrsUS$151.21k0.80%
$ 1.4m
Anthony Quinn
Independent Director6.7yrsUS$143.71k0.24%
$ 430.8k
Andrew Scharenberg
Chairman of Scientific Advisory Boardno datapas de donnéespas de données
Donald Nicholson
Independent Director6.7yrsUS$143.71k0.32%
$ 570.3k
Kevin Fitzgerald
Member of Scientific Advisory Boardno datapas de donnéespas de données
Adrian Thrasher
Member of Scientific Advisory Boardno datapas de donnéespas de données
Ronald H. Cooper
Independent Director3.4yrsUS$144.21k0.014%
$ 25.4k
Catherine Stehman-Breen
Independent Director6.7yrsUS$143.71k0.071%
$ 126.9k
Richard Thompson
Member of Scientific Advisory Board5.8yrspas de donnéespas de données

6.7yrs

Durée moyenne de l'emploi

61yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de GBIO sont considérés comme expérimentés (ancienneté moyenne 6.7 ans).